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Abstract
Treatment of Guillain-Barre syndrome with a standard course of high-dose
intravenous immunoglobulin (IVIg) results in a variable clinical recovery which
is associated with changes in serum IgG levels after treatment. The neonatal Fc-
receptor protects IgG from degradation, and a genetic polymorphism in its pro-
moter region that influences the expression of Fc-receptor, may in part explain
the variation in IgG levels and outcome. This polymorphism was determined
by polymerase chain reaction in a cohort of 257 patients with Guillain-Barre
syndrome treated with IVIg. We could not demonstrate a relation between this
polymorphism, the pharmacokinetics of IVIg, or the clinical course and out-
come.
Introduction
Intravenous immunoglobulins (IVIg) is the first choice
treatment for the Guillain-Barre syndrome (GBS).1
Patients with GBS are usually treated with a 5-day stan-
dard regimen of in total 2 g/kg bodyweight of IVIg, inde-
pendent of disease severity.1 A previous study showed
that the serum IgG levels reached after 2 weeks vary lar-
gely between patients, and that a relatively low IgG
increase is related to poor recovery.2 At present it is
unknown which mechanism determines this variation in
the pharmacokinetics of IVIg. Identification of an under-
lying genetic factor(s) influencing IgG’s kinetics would be
a crucial step toward individualized dosing.
The neonatal Fc receptor (FcRn) protects IgG from
degradation by binding and recycling IgG back into the
circulation.3–5 When saturated by supraphysiological
levels of IgG, the excess IgG will be degraded instead of
recycled.3 The expression level of this receptor is influ-
enced by a polymorphism in the promoter region of the
gene-encoding FcRn.6 A variable number of tandem
repeats (VNTR) in the promoter of the FcRn alpha-chain
gene, ranging from VNTR1-5, results in different expres-
sion levels of FcRn mRNA and protein.7 Previous studies
in immunodeficient patients showed that this polymor-
phism influences the pharmacokinetics of IVIg.8 Patients
homozygous for the VNTR3 allele (VNTR 3/3, relatively
high FcRn expression) had higher IgG trough levels and
higher IVIg efficiency than VNTR 3/2 heterozygous
patients (relatively low FcRn expression).8
We hypothesized that the VNTR in the FcRn promoter
region influences the pharmacokinetics of IVIg in patients
with GBS, thereby explaining the variation in IgG levels
found previously and possibly the poor clinical outcome
associated with a low IgG increase. This hypothesis was
tested in a large cohort of patients for whom standardized
serial serum samples and detailed clinical follow-up data
were available.
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DNA and clinical data were available from 257 patients
with GBS, previously included in clinical trials coordi-
nated by our center that investigated the therapeutic effect
of IVIg.9–11 All gave informed consent after prior
approval by the appropriate Institutional Review Board,
additional informed consent was obtained for genetic
studies.12 All patients met the diagnostic criteria for
GBS,13 were included within 2 weeks of onset of weak-
ness, and were treated with a standard regimen of IVIg of
2 g per kg bodyweight administered over 5 days. Addi-
tional serum samples obtained pretreatment, at 2 and
4 weeks, and at 3 and 6 months after start of IVIg were
available from 98 (38%) patients to determine IgG con-
centrations. These 98 patients did not differ from the
remaining patients with respect to demographic charac-
teristics, treatment, disease severity at entry, or clinical
course and outcome. The delta-IgG level (ΔIgG) was
defined as the increase in IgG level after 2 weeks com-
pared to the pretreatment sample.2 Predefined measures
for clinical course and outcome were used, including the
GBS disability score (ranging 0–6, healthy death), the
need for mechanical ventilation, and the Medical Research
Council (MRC) sum score (ranging 0–60 [total paralysis
– normal strength]) before treatment, at nadir and at
6 months.13,14 All samples were stored at 80°C until
use.
Data collection
Genomic DNA was isolated from EDTA anticoagulated
peripheral blood samples, using invicorb MaxiBlood kit
(Invitek, Berlin, Germany) according to the instructions
of the manufacturer. The VNTR genotype was determined
using the polymerase chain reaction (PCR) on GeneAmp
PCR System 2700 according to Sachs et al., with minor
modifications.7 Briefly, 80 ng of DNA was added to a
mastermix of 2 lL MgCl (25 mmol/L), 1.0 lL (12.5
pmol/lL) of both forward (50-GGCTGGGGGTCTCGA
CACT- 30) and reverse (50-AGTCTGGACCGAGCCCGC-
30) primer (flanking the VNTR sequence), 0.5 lL
deoxynucleotide triphosphate (dNTP) (20 nmol/L), and
0.2 lL Taq polymerase, in a total volume of 20 lL. Anal-
ysis of PCR products was performed using 2.0% agarose
gels. We performed fluorescent fragment length analysis
(GeneScan) according to the manufacturer protocols
using a 6FAM labeled reverse primer (50-(6FAM)GCGG
GCTCGGTCCAGACT-30), in a select number of patients
(n = 25) to validate the PCR and gel electrophoresis
technique.
Statistical analysis
Statistical analysis was performed using SPSS (IBM Corp.,
Version 21.0. Armonk, NY, USA) and Graphpad Prism
software (GraphPad Software, Version 5.0, La Jolla, CA,
USA). The effect of VNTR genotype on IgG serum levels
was tested with an independent samples t-test. Clinical
outcome scores between VNTR genotypes were compared
using v2-test for categorical data and independent sam-
ples t-test for numerical data. Mann–Whitney U test was
used for nonnormal distributed numerical data. When
necessary we corrected for confounding factors using
ANCOVA, otherwise ANOVA was used. Survival analysis
was performed by Kaplan–Meier analysis (log rank). Sta-
tistical significance was defined as a two-sided P < 0.05.
Results
PCR and gel electrophoresis analysis of DNA from 257
GBS patients identified five different FcRn VNTR alleles,
resulting in 7 distinctive FcRn VNTR genotypes (Fig. 1).
The VNTR allele frequencies were 0.2% (VNTR1), 9.1%
(VNTR2), 89.5% (VNTR3), 0.8% (VNTR4), and 0.4%
(VNTR5). The distributions of allele frequencies followed
the Hardy–Weinberg equilibrium. The two predominant
genotypes were VNTR 3/3 found in 207 patients
(80.5%) and VNTR 3/2 in 40 patients (15.6%). Other
rarer genotypes were found in the remaining 10 patients
Figure 1. Representative examples of the different variable number
of tandem repeats (VNTR) genotypes identified using polymerase
chain reaction (PCR) and gel electrophoresis. PCR revealed 5
distinctive VNTR alleles, based on a repetitive genetic motif of 37 base
pairs in size, and 7 different genotypes (lane 1–7). The derived VNTR
sizes were as follows: VNTR 1 (389 bp); VNTR 2 (426 bp); VNTR 3
(463 bp); VNTR 4 (500 bp); and VNTR 5 (537 bp). The two flanking
lanes are PCR molecular weight ladders (M) with 100 bp difference in
size. For each genotype, the number and percentage of patients was
indicated.
548 ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
FcRn Promoter Polymorphism in GBS W.-J. R. Fokkink et al.
(3.8%), for example. VNTR 5/3, 4/3, 4/2, 3/1, and 2/2
(Fig. 1). The VNTR genotypes found by PCR were
confirmed by fluorescent fragment length analysis
(Fig. S1).
Patients with the VNTR 3/3 genotype did not differ
from patients with the VNTR 3/2 genotype regarding
demographics or signs of preceding infection, with the
exception of a higher percentage of males in the VNTR
3/2 group (Table 1). In the subgroup where IgG levels
were available (n = 98), 82 patients (84%) had VNTR 3/
3, 15 patients (16%) had VNTR 3/2, and 1 patient (1%)
had VNTR 4/3. The mean dose of administered IVIg did
not differ between the genotype groups: 135 (SD = 57 g)
in the VNTR 3/3 subgroup and 146 (SD = 51 g) in the
VNTR 3/2 subgroup. Serum IgG level before and at 2
and 4 weeks after start of IVIg and the ΔIgG did not dif-
fer between the VNTR 3/3 and VNTR 3/2 subgroups
(Fig 2). However, serum IgG levels at 3 and 6 months
after IVIg treatment were higher in patients with VNTR
3/2 than in the VNTR 3/3 homozygotes (P = 0.004,
Fig 2).
The group of 247 patients (VNTR 3/3 and 3/2) was
used to determine whether there was a relation between
the VNTR genotype and the clinical course and outcome.
The GBS disability scores and MRC sum scores did not
differ between patients with various VNTR genotypes at
entry, nadir, or at the end of follow-up (Table 1), or at
Table 1. Baseline characteristics, clinical severity, and clinical outcome of 247 patients based on variable number of tandem repeats (VNTR) in the
promoter of the FcRn alpha-chain gene.
Baseline characteristics
Genotype
P-valueVNTR 3/3 (n = 207) VNTR 3/2 (n = 40)
Age (years) 49.5 (16.1) 52.0 (17.0) ns
Males 108 (52.2%) 28 (70.0%) 0.038
Body weight 74.4 (14.5) (n = 112) 78.4 (12.0) (n = 22) ns
Preceding
diarrhea




78 (39%) (n = 201) 13 (33%) (n = 39) ns
Clinical severity at entry
Mean GBS disability
score at entry
3.6 (0.8) (n = 206) 3.4 (0.9) (n = 39) ns
Mean MRC sum
score at entry
44.4 (9.9) (n = 202) 43.5 (12.5) (n = 38) ns
Clinical severity during follow-up
Mean GBS disability
score at nadir
3.9 (0.9) 3.8 (1.0) ns
Mean MRC sum
score at nadir
38.0 (15.4) (n = 206) 37.6 (17.4) (n = 40) ns
Mechanical
ventilation
41 (20%) 11 (28%) ns
GBS disability score
at 6 months
1.4 (1.1) (n = 199) 1.5 (1.1) (n = 40) ns
Data are presented as mean (sd) or as number (percentage).
Ns, not significant; IVIg, intravenous immunoglobulin
Figure 2. Serum Immunoglobulin G (IgG) levels before treatment,
after treatment at standardized time points (2, 4, 14, and 26 weeks)
and the difference between the IgG level after 2 weeks and pr-
treatment IgG level (ΔIgG). Groups are based on FcRn promoter
alpha-chain genotype, variable number of tandem repeats (VNTR).
Data presented as mean and whiskers according to Tukey. * denotes
a significant difference.
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important clinical assessment points (2 and 4 weeks,
Table S1). In addition, there was no association between
VNTR genotype and the time to regain the ability to walk
independently or to improve 1 point on the GBS disabil-
ity scale (Fig. S2).
Discussion
IVIg is used in a broad spectrum of disorders, either for
replacement or immune modulation, and the pharma-
cokinetics of IVIg are important to facilitate personalized
medicine. Metabolism of IgG is governed by FcRn and a
polymorphism in the promoter region influences the
expression of this receptor.7 This study assessed whether
a particular FcRn polymorphism in GBS patients treated
with IVIg has an effect on the degree of increase in the
IgG level; and whether it influences the course of disease
in GBS. We found no association between this func-
tional genetic polymorphism in the promoter region of
the FcRn gene and the pharmacokinetics of IVIg, or
with the clinical outcome after IVIg in patients with
GBS.
The current knowledge of the pharmacokinetics of IVIg
is largely based on studies in patients with immunodefi-
ciencies receiving replacement therapy.15 Pretreatment
IgG levels (ranging from <1.5 g/L to <6 g/L) are impor-
tant in these conditions for subsequent IVIg dosing.15,16
However, this cannot be extrapolated to GBS patients
with normal serum IgG levels. A second difference is the
treatment regimen, as most patients with immune defi-
ciencies receive low dosages at regular intervals (~0.4 g/
kg/month).16 In contrast, high-dose IVIg in GBS, super-
imposed on the normal endogenous IgG serum level,
increases IgG by up to five times the normal serum
level.17 The concentration-dependent clearance of IgG
and the role of FcRn herein is probably very different. A
recent small study in multifocal motor neuropathy (18
patients were genotyped) treated with IVIg (same regimen
as in GBS) found similar results to this work: no associa-
tion between the polymorphism in the FcRn gene and the
serum IgG levels.18 However, we cannot completely rule
out a small effect of FcRn polymorphism on IVIg phar-
macokinetics. The 2-week interval between the pre- and
posttreatment IgG-level measurement could mask more
subtle differences, as found previously for immune-defi-
cient patients requiring replacement therapy.8,16 Whether
this possible small effect on IgG levels after treatment has
any impact on clinical outcome is, however, unlikely, as
we found no association between the FcRn polymorphism
and clinical outcome in GBS. A study in lupus nephritis,
a disease in which autoantibodies play a dominant role in
the pathogenesis, also reported no association of the FcRn
polymorphism with outcome.19
This study was conducted in a representative cohort
of patients with GBS who were treated with a standard
course of IVIg. The distribution of the frequency of the
various VNTR genotypes in the group of GBS patients
was similar to that previously reported in healthy con-
trols, indicating that this genetic polymorphism does
not generally predispose to GBS.7,8 Although clinical
data were available for the full cohort, IgG data were
limited, and the apparent differences found at 3 and
6 months may very well be due to this limited group
size.
Other factors influencing the turnover of antibodies or
affecting FcRn expression could play a role: for instance,
serum proteases degrading the IgG molecules or cytokine-
induced regulation of FcRn expression, especially under
the inflammatory conditions in GBS, could overrule the
underlying genotype;20–22 providing an explanation as to
why the FcRn promoter gene polymorphism influences
IVIg pharmacokinetics in immunodeficient patients on
replacement therapy, but not patients with this inflamma-
tory disease of the peripheral nerves.
Acknowledgment
This work has been supported by a grant from the Prinses
Beatrix Spierfonds (grant W.OR11-27).
Author contribution
B.C.J. and W.J.R.F. designed the study. A.E.G.H., A.P.T-
G., W.vR., and W.J.R.F. performed the experiments.
W.J.R.F. and A.E.G.H. analyzed the data. W.J.R.F.,
A.E.G.H., R.H.G.H., P.A.vD, and B.J.C. drafted the manu-
script. B.C.J. supervised this study. All authors read and
approved the final version of the manuscript.
Conflicts of Interest
Dr. Jacobs reports grants from Prinses Beatrix Spierfonds,
during the conduct of the study; grants from Netherlands
Organization for Health Research and Development,
Erasmus Medical Center, Prinses Beatrix Spierfonds,
GBS-CIDP Foundation International, Baxter Biopharma-
ceutics, CSL-Behring, Grifols, outside the submitted work.
Dr. van Doorn reports grants from Sanguin blood supply,
Baxalta, Grifols, Prinses Beatrix Spierfonds, Janivo Founda-
tion, outside the submitted work. Dr. Huizinga reports
grants from the Dutch Prinses Beatrix Spierfonds, during
the conduct of the study; grants from the Dutch Prinses
Beatrix Spierfonds, grants from the GBS-CIDP Foundation
International, outside the submitted work. Dr. Fokkink
reports grants from Prinses Beatrix Spierfonds, during the
conduct of the study.
550 ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
FcRn Promoter Polymorphism in GBS W.-J. R. Fokkink et al.
References
1. van den Berg B, Walgaard C, Drenthen J, et al. Guillain-
Barre syndrome: pathogenesis, diagnosis, treatment and
prognosis. Nat Rev Neurol 2014;10:469–482.
2. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al.
Pharmacokinetics of intravenous immunoglobulin and
outcome in Guillain-Barre syndrome. Ann Neurol
2009;66:597–603.
3. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor
comes of age. Nat Rev Immunol 2007;7:715–725.
4. Tesar DB, Bjorkman PJ. An intracellular traffic jam: Fc
receptor-mediated transport of immunoglobulin G. Curr
Opin Struct Biol 2010;20:226–233.
5. Rath T, Baker K, Pyzik M, Blumberg RS. Regulation of
immune responses by the neonatal fc receptor and
its therapeutic implications. Front Immunol 2014; 5:664.
6. Mikulska JE, Pablo L, Canel J, Simister NE. Cloning and
analysis of the gene encoding the human neonatal Fc
receptor. Eur J Immunogenet 2000;27:231–240.
7. Sachs UJ, Socher I, Braeunlich CG, et al. A variable
number of tandem repeats polymorphism influences the
transcriptional activity of the neonatal Fc receptor alpha-
chain promoter. Immunology 2006;119:83–89.
8. Gouilleux-Gruart V, Chapel H, Chevret S, et al. Efficiency
of immunoglobulin G replacement therapy in common
variable immunodeficiency: correlations with clinical
phenotype and polymorphism of the neonatal Fc receptor.
Clin Exp Immunol 2013;171:186–194.
9. van der Meche FG. Schmitz PI. A randomized trial
comparing intravenous immune globulin and plasma
exchange in Guillain-Barre syndrome. Dutch Guillain-
Barre Study Group. N Engl J Med 1992;326:1123–1129.
10. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of
methylprednisolone when added to standard treatment
with intravenous immunoglobulin for Guillain-Barre
syndrome: randomised trial. Lancet 2004;17:192–196.
11. Ruts L, Drenthen J, Jongen JL, et al. Pain in Guillain-Barre
syndrome: a long-term follow-up study. Neurology
2010;19:1439–1447.
12. Geleijns K, Jacobs BC, Van Rijs W, et al. Functional
polymorphisms in LPS receptors CD14 and TLR4 are not
associated with disease susceptibility or Campylobacter
jejuni infection in Guillain-Barre patients. J
Neuroimmunol 2004;150(1–2):132–138.
13. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM.
Controlled trial prednisolone in acute polyneuropathy.
Lancet 1978;2:750–753.
14. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver
agreement in the assessment of muscle strength and
functional abilities in Guillain-Barre syndrome. Muscle
Nerve 1991;14:1103–1109.
15. Bonilla FA. Pharmacokinetics of immunoglobulin
administered via intravenous or subcutaneous routes.
Immunol Allergy Clin North Am 2008;28:803–819. , ix.
16. Cunningham-Rundles C. How I treat common variable
immune deficiency. Blood 2010;8:7–15.
17. Dalakas MC. High-dose intravenous immunoglobulin and
serum viscosity: risk of precipitating thromboembolic
events. Neurology 1994;44:223–226.
18. Vlam L, Cats EA, Willemse E, et al. Pharmacokinetics of
intravenous immunoglobulin in multifocal motor neuropathy.
J Neurol Neurosurg Psychiatry 2014;85:1145–1148.
19. Zhou XJ, Yu L, Zhu L, et al. Association between
polymorphisms in the FCGRT gene and lupus nephritis in
Chinese patients. Clin Exp Rheumatol 2009;27:609–614.
20. Liu X, Ye L, Christianson GJ, et al. NF-kappaB signaling
regulates functional expression of the MHC class I-related
neonatal Fc receptor for IgG via intronic binding
sequences. J Immunol 2007;179:2999–3011.
21. Liu X, Ye L, Bai Y, et al. Activation of the JAK/STAT-1
signaling pathway by IFN-gamma can down-regulate
functional expression of the MHC class I-related
neonatal Fc receptor for IgG. J Immunol 2008;181:449–
463.
22. Qiao SW, Lencer WI, Blumberg RS. How the controller is
controlled - neonatal Fc receptor expression and
immunoglobulin G homeostasis. Immunology
2007;120:145–147.
Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. Fragment length analysis by Genescan of
VNTR of the FcRn promoter region. Confirming the
genotypes found by PCR gel electrophoresis: VNTR 5/3,
VNTR 4/3, VNTR 4/2, VNTR 3/3, VNTR 3/2, VNTR 3/1,
and VNTR 2/2. Red lines represent the size standard ref-
erence lines, used to size the PCR products and create the
x-axis. Blue peaks indicate VNTR PCR product and the
peak position on the x-axis indicates base pair size of
product, from which the according VNTR genotype can
be derived.
Figure S2. Cumulative proportion of patients who
improve 1 point at the GBS disability scale (F-score) or
regaining of the ability to walk unaided during follow-up.
Table S1. Clinical severity as scored at the end of the 1st,
2nd, and 4th week of 141 GBS patients based on variable
number of tandem repeats (VNTR) in the promoter of
the FcRn alpha-chain gene. Data are presented as mean
(sd) or as number (percentage). ns= not significant; IVIg=
intravenous immunoglobulin
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